Advanced Cancer Therapeutics said today that it has exclusively licensed the rights to develop and commercialize small-molecule inhibitors of choline kinase as cancer therapeutics from the University of Louisville's James Graham Brown Cancer Center.

The agreement is the fifth licensing deal, and fourth in the area of cancer therapeutics, inked between U of L and ACT since the company was founded in 2007 by local venture capitalists and U of L's tech-transfer office to serve as a commercialization "pipeline" for anti-cancer compounds discovered at the school.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.